Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05169658
Title Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington

follicular lymphoma

marginal zone B-cell lymphoma

non-Hodgkin lymphoma


Mosunetuzumab + Obinutuzumab + Polatuzumab vedotin-piiq

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.